CMO Letter to Reduce Inappropriate Antibiotic Prescribing Winter 2019/2020

NCT ID: NCT04051281

Last Updated: 2020-09-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

2963 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-08-31

Study Completion Date

2020-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial aims to reduce inappropriate prescription of antibiotics and broad spectrum antibiotics by general practitioners (GPs) in England. Unnecessary prescriptions are defined as those that do not improve patient health outcomes. The intervention is to send GPs a letter from the Chief Medical Officer (CMO) that gives feedback on their practice's prescribing levels.

There will be three intervention samples:

1. practices whose prescribing in the past year was under the new target of 0.965 items per STAR-PU but who would exceed the target if they had a 5% increase in prescribing; trial compares prescribing of practices whose GPs receive a letter informing them that their practice's prescribing is just under the new target to that of practices that are not sent a letter
2. Practices whose prescribing in the past year was above the new target but who not in the top 20% of prescribers; trial compares prescribing of practices whose GPs receive a letter informing them that their practice's prescribing exceeds the new target to practices who get a letter that includes a graph showing their prescribing relative to the target and to practices that are not sent a letter
3. Practices that are currently in the top 20% of prescribers; trial compares effect on prescribing of a feedback letter with a social norms message (current standard practice for this group) to a letter informing GPs that their practice's prescribing exceeds the new target and to a letter with a social norms message, that includes a specific example of a case of patient harm caused by antimicrobial resistance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will involve three trials, each conducted as non-blinded randomised controlled trial, with GP practices as the unit of randomisation.

Trial 1 Targeting practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing

* Control: No letter
* Intervention: Letter informing them that their practice's prescribing is just under the new target (Letter A) Trial hypothesis: Sending a letter to GPs whose practices are just under the new prescribing target will reduce antibiotic prescribing

Trial 2 Targeting practices whose prescribing in the past year was above the new target but who not in the top 20% of prescribers

* Control: No letter
* Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter B1)
* Intervention 2: Letter informing them that their practice's prescribing exceeds the new target with a graph representing prescribing relative to the target (Letter B2) Hypotheses: (i) Sending a letter to GPs whose practices missed the new prescribing target will reduce their prescribing; (ii) A letter with a graph will be more effective than a letter without a graph.

Trial 3 Targeting practices that are currently in the top 20% of prescribers

* Control: Current standard practice, a social norms message, that their practice is in the top 20% of prescribers (Letter C1)
* Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter C2)
* Intervention 2: Social norms message, that they are in the top 20%, with a specific example of a case of patient harm caused by antimicrobial resistance (Letter C3)

Hypotheses: (i) A letter with a social norms message and a specific example of a case where a patient came to harm will be more effective than a feedback letter without a specific example; (ii) A letter telling GPs that they missed the prescribing target will be no less effective than a letter with social norms feedback

For each letter, there will be two versions, one for practices whose prescribing has increased by \> 5% in the previous year, informing them of that their prescribing has increased since the previous year, and one for practices whose prescribing has not been increasing.

The letters will signpost GPs to resources to help address patient demand for inappropriate antibiotic prescribing, recognising that many GPs feel that patients expect antibiotics and that GPs may find it difficult to have the necessary patient conversations, especially within a short consultation. As with previous letters, these letters will advise GPs of actions that they can take to reduce inappropriate prescribing, supporting them to have conversations with patients, and there will be TARGET leaflets enclosed.

Power calculation All trials are powered to detect a 2% reduction in prescribing at a significance level of 0.05 with a power of 80%.

Statistical analysis plan In order to test our hypotheses, the investigators will use a fixed effects panel regression model, with time trends accounting for seasonal effects, to estimate the effect of treatment status on prescribing. The investigators will also run ANCOVAs for each month separately and one covering the whole six months of the trial. Analysis will control for baseline prescribing rates and for whether practices got the version of the letter saying that their prescribing has been increasing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prescribing, Off-Label

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Just under target control

Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing; no letter sent.

Group Type NO_INTERVENTION

No interventions assigned to this group

Just under target letter

Practices whose prescribing in the past year was under the new target but who would exceed the target if they had a 5% increase in prescribing: receive a letter informing of this.

Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter

Group Type EXPERIMENTAL

Letter

Intervention Type BEHAVIORAL

Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Over target control

Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; no letter sent

* Intervention 1: Letter informing them that their practice's prescribing exceeds the new target (Letter B1)
* Intervention 2: Letter informing them that their practice's prescribing exceeds the new target with a graph representing prescribing relative to the target (Letter B2)

Group Type NO_INTERVENTION

No interventions assigned to this group

Over target letter

Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target (Letter B1)

Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter

Group Type EXPERIMENTAL

Letter

Intervention Type BEHAVIORAL

Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Over target letter with bar chart

Practices whose prescribing in the past year was above the new target but who were not in the top 20% of prescribers; receive a letter informing them that their practice's prescribing exceeds the new target, including a bar chart showing their prescribing compared to the target (Letter B1)

Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter

Group Type EXPERIMENTAL

Letter

Intervention Type BEHAVIORAL

Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Top 20% feedback letter control

Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on--standard practice--(Letter C1)

Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter

Group Type ACTIVE_COMPARATOR

Letter

Intervention Type BEHAVIORAL

Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Top 20% above target letter

Targeting practices that are currently in the top 20% of prescribers; letters informing them that their prescribing exceeds the new target (Letter C2)

Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter.

Group Type EXPERIMENTAL

Letter

Intervention Type BEHAVIORAL

Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Top 20% feedback letter with specific example of patient harm

Targeting practices that are currently in the top 20% of prescribers

• Control: Current standard practice, a social norms message, that their practice is in the top 20% of prescribers (Letter C1) Targeting practices that are currently in the top 20% of prescribers; letters informing them of the percentile they are on with a specific example of a case of patient harm caused by antimicrobial resistance (Letter C3)

Randomization is stratified according to whether their prescribing had increased by \> 5% compared to the previous year; those whose prescribing had increased had it mentioned in the letter.

Group Type EXPERIMENTAL

Letter

Intervention Type BEHAVIORAL

Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Letter

Letters sent to GPs in relevant practices (prescribing data is by practice, so the practice is the unit of randomization)

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• GP practices that prescribed more than 0.919 Antibacterial Items/STAR- PU (5% under the target of 0.965) for the twelve months April 2018 - March 2019

Exclusion Criteria

• Practices in the 99th percentile of prescribers
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Public Health England

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Public Health England

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CMO Letter 2019/20

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Optimizing Antibiotics Prescription
NCT06436690 ACTIVE_NOT_RECRUITING NA